The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•13 February 2026•

1 min read

Rhumbline Advisers Trims VRTX Stake Amidst Mixed Institutional Moves and Positive Analyst Outlook

A man in a suit, Uber and Nissan logos, and futuristic autonomous cars with sensors in a glowing Tokyo city scene.

Rhumbline Advisers reduced its stake in Vertex Pharmaceuticals (NASDAQ:VRTX) by 1.4% during the third quarter. The firm now holds 447,928 shares in VRTX, valued at $175.43 million. This adjustment occurs amidst reports of other institutional investors, such as Chesapeake Asset Management LLC and Financial Network Wealth Advisors LLC, increasing their positions in the stock. Conversely, analysts maintain an average "Moderate Buy" rating for VRTX. The average price target for the stock stands at $522.68, indicating analyst confidence in its future prospects. These movements reflect routine adjustments in institutional investment portfolios and an ongoing assessment of Vertex Pharmaceuticals' performance and outlook.

Sources: